Zobrazeno 1 - 10
of 93
pro vyhledávání: '"YMDD mutation"'
Autor:
Hongcan Liu, Zemin Wan, Lanhui She, Yajuan Zhu, Zhiliang Cai, Bin Wu, Qizhen Zhuang, Peifeng Ke, Xinzhong Wu, Zhuo Li, Xianzhang Huang
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background/Aims: Emergence of tyrosine-methionine-aspartate-aspartate (YMDD) motif in reverse transcriptase is a serious problem in chronic hepatitis B(CHB) patients after Lamivudine (LAM) therapy. However, the relationship between inflammation pharm
Externí odkaz:
https://doaj.org/article/3e933334fed84cf78b5f71d9165f364a
Publikováno v:
Medical Laboratory Journal, Vol 8, Iss 5, Pp 7-13 (2015)
Abstract Background and Objective: Lamivudine is the first orally available drug approved for treatment of chronic hepatitis B. Mutations at the YMDD and FLLAQ motifs in the domains of HBV polymerase gene contribute resistance to lamivudine. This stu
Externí odkaz:
https://doaj.org/article/8947ffa5e7274bedb512c399387cace9
Autor:
Zemin Wan, Yajuan Zhu, Xianzhang Huang, Bin Wu, Zhuo Li, Lanhui She, Xinzhong Wu, Hongcan Liu, Qi-Zhen Zhuang, Peifeng Ke, Zhiliang Cai
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Background/Aims: Emergence of tyrosine-methionine-aspartate-aspartate (YMDD) motif in reverse transcriptase is a serious problem in chronic hepatitis B(CHB) patients after Lamivudine (LAM) therapy. However, the relationship between inflammation pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfbdec64b11277fae71a0d8a217050d0
https://doi.org/10.3389/fphar.2021.648170
https://doi.org/10.3389/fphar.2021.648170
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wooseong Huh, Hye Ryoun Jang, Joon Hyeok Lee, Jae Berm Park, Jae-Won Joh, Choon Hyuck David Kwon, Sung Joo Kim, Hyojun Park, Jong Man Kim
Publikováno v:
Annals of Surgical Treatment and Research
Purpose: HBsAg-positive kidney recipients are at increased risk for mortality and graft failure. The aims of this study were to identify the outcomes of HBsAg-positive recipients who received preemptive antiviral agents after successful kidney transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cbf9bb0d87bb74c91fa1f36135e24cd
http://europepmc.org/articles/PMC4024934
http://europepmc.org/articles/PMC4024934
Autor:
Yong-hua Zhang, Hui Feng
Publikováno v:
Chinese Journal of Integrative Medicine. 16:19-22
To observe the effect of Chinese medicine therapy for strengthening-Pi and nourishing-Shen (SPNS) in preventing lamivudine induced YMDD mutation and its immunological mechanism.One hundred and sixty chronic hepatitis B (CHB) patients with positive HB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::334645bacf73b781bf55947d6accf2d0
https://doi.org/10.1007/s11655-010-0019-x
https://doi.org/10.1007/s11655-010-0019-x
Publikováno v:
Evidence-based Complementary and Alternative Medicine : eCAM
Evidence-Based Complementary and Alternative Medicine, Vol 2015 (2015)
Evidence-Based Complementary and Alternative Medicine, Vol 2015 (2015)
Oxymatrine (OMTR) is widely used for the treatment of chronic hepatitis B (CHB) in China. Several reports revealed that combination of OMTR and lamivudine reduced the incidence of tyrosine- (Y-) methionine- (M-) aspartic acid- (D-) aspartic acid (D)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c58e0be744f658dc565f3e869fc380
https://pubmed.ncbi.nlm.nih.gov/26508988
https://pubmed.ncbi.nlm.nih.gov/26508988
Autor:
Satsuki Kobayashi
Publikováno v:
The Kurume Medical Journal. 50:87-90
We previously developed a method of detecting drug-resistant mutation of hepatitis B virus (tyrosine (Y)-methionine (M)-aspartic acid (D)-aspartic acid (D) (YMDD) mutation) caused by the antiviral agent lamivudine. Using this method, we also reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c8cad44a34cafa65f22113d198c2db
https://doi.org/10.2739/kurumemedj.50.87
https://doi.org/10.2739/kurumemedj.50.87
Publikováno v:
Internal Medicine. 45:1213-1215
We report a patient whose cryoglobulinemic vasculitis recurred due to reactivation of lamivudine-resistant HBV. Our patient with hepatitis B-related cryoglobulinemic vasculitis was administered lamivudine. Her vasculitis regressed, ALT normalized, HB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8f5b5a66b80c8fb2496c69a3feb266c
https://doi.org/10.2169/internalmedicine.45.1816
https://doi.org/10.2169/internalmedicine.45.1816